Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(3)
•••
Comment by BSmartStaycalmon Jun 17, 2018 10:59am
150 Views
Post# 28183011

RE:Surrender of patents for IMMUNOGENIC FORMULATION

RE:Surrender of patents for IMMUNOGENIC FORMULATION
BSmartStaycalm wrote:
Part II of II - E-Journal Online Previewer - CIPC ejournal.cipc.co.za/PublishedJournals/E_Journal_July%202017%20Part%202.pdf 1 Jul 2017 ... APPLICATION FOR VOLUNTARY SURRENDER OF PATENTS UNDER SECTION 64 (1), REGULATION 67 OF THE ACT ...... 2016/02148 of 30 September 2014 for IMMUNOGENIC FORMULATION ..... THEREOF ~71: PROMETIC BIO THERAPEUTICS, INC., 1330 Piccard Drive, Suite 201, Rockville, 20850,.


Recombinant BCG as a vaccine vehicle to protect against... www.ncbi.nlm.nih.gov/pmc/articles/PMC3026451/ 2 Nov 2009 ... 2010 Mar-Apr; 1(2): 110115. ... The vaccine is immunogenic and is stable and cheap to produce. Additionally, the vaccine can be engineered to express foreign ... Key words: recombinant BCG, tuberculosis, vaccine, protective ... However, the pressing need for development of new vaccines to contain the ... Surrender of patents for IMMUNOGENIC FORMULATION This is old news and relates to using BCG to deliver medication.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities